AbbVie's Imbruvica misses pancreatic cancer endpoints

AbbVie Inc. (NYSE:ABBV) said late Friday Imbruvica ibrutinib missed the co-primary endpoints in the Phase III RESOLVE (PCYC-1137) trial as part of a first-line combination treatment of metastatic pancreatic cancer. In 424 patients, the Bruton's tyrosine kinase (Btk) inhibitor plus chemotherapy failed to improve progression-free survival or overall survival vs. placebo plus chemotherapy.

Full data from the trial will be submitted for presentation at an upcoming scientific meeting or published in a peer-reviewed medical journal. AbbVie did not respond to inquiries regarding its next steps for Imbruvica in the indication...